Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research

Journal of Medical Genetics

Volumn 47, Issue 7, 2010, Pages 436-444

  Fitzgerald, Rebecca C ^a,b,c   Hardwick, Richard ^b   Huntsman, David ^d   Carneiro, Fatima ^e   Guilford, Parry ^f   Blair, Vanessa ^f   Chung, Daniel C ^g   Norton, Jeff ^h   Ragunath, Krishnadath ⁱ   Van Krieken, J Han ^j   Dwerryhouse, Sarah ^k   Caldas, Carlos ^c,l  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e University of Porto   (Portugal)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ QUEEN S MEDICAL CENTRE   (United Kingdom)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^l CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COLON CANCER; CONSENSUS; DISEASE SURVEILLANCE; DNA SEQUENCE; ENDOSCOPY; FAMILIAL CANCER; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PEDIGREE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STOMACH CANCER; SURGICAL TECHNIQUE; TOTAL STOMACH RESECTION; ADULT; ALGORITHM; CYTOCHEMISTRY; DECISION SUPPORT SYSTEM; DECISION TREE; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; EPITHELIUM; FACTUAL DATABASE; FEMALE; GENETICS; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; STOMACH MUCOSA; STOMACH NEOPLASMS;

ADULT; ALGORITHMS; CADHERINS; DATABASES, FACTUAL; DECISION SUPPORT SYSTEMS, CLINICAL; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; ENDOSCOPY, GASTROINTESTINAL; EPITHELIUM; FEMALE; GASTRIC MUCOSA; GENETIC COUNSELING; HISTOCYTOCHEMISTRY; HUMANS; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; PRACTICE GUIDELINES AS TOPIC; STOMACH NEOPLASMS;

EID: 77956110372     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.074237     Document Type: Article

References (61)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7. (Pubitemid 26113739)
3. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 1995;32:942-5.
4. La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992;70:50-5.
5. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999;36:873-80.
6. Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE, Seruca R, Caldas C. Screening E-cadherin in gastric cancer families reveals germ-line mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19:510-17.
7. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5. (Pubitemid 28168738)
8. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008;216:295-306.
9. Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009;136:2137-48.
10. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-53.
11. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-72.
12. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006;4:262-75. (Pubitemid 43343880)
13. Oliveira C, Moreira H, Seruca R, de Oliveira MC, Carneiro F. Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. Virchows Arch 2005;446:181-4.
14. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006;14:21-33.
15. Suriano GYS, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a recurrent germ line mutation of the e-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 2005;11:5401-9.
16. Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009;18:1545-55.
17. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
18. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-46. (Pubitemid 34233019)
19. Suriano G, Oliveira C, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C, Seruca R. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003;12:575-82.
20. Suriano G, Seixas S, Rocha J, Seruca R. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 2006;84:1023-31.
21. Barber ME, Save V, Carneiro F, Dwerryhouse S, Lao-Sirieix P, Hardwick RH, Caldas C, Fitzgerald RC. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 2008;216:286-94.
22. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004;53:814-20.
23. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simões M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203:681-7.
24. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344:1904-9. (Pubitemid 32553359)
25. Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001;130:612-17; discussion 617-19.
26. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001;92:181-7.
27. Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Kingham K, Chun N, Ford JM, Longacre TA. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008;32:799-809.
28. Shaw DBV, Framp A, Harawira P, McLeod M, Guilford P, Parry S, Charlton A, Martin I. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 2005;54:461-8.
29. Dunbar K, Canto M. Confocal endomicroscopy. Curr Opin Gastroenterol 2008;24:631-7.
30. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873-9.
31. Koea JB, Karpeh MS, Brennan MF. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol 2000;7:346-51.
32. Brennan MF. Safety in numbers. Br J Surg 2004;91:653-4.
33. Brennan MF. Pre-emptive surgery and increasing demands for technical perfection. Br J Surg 2003;90:3-4.
34. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992;79:241-4.
35. Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, Ayazi S, Leers JM, Lipham JC, Hagen JA, DeMeester TR. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 2007;246:665-71; discussion 671-4.
36. Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 2005;20:517-25.
37. Fein M, Fuchs KH, Thalheimer A, Heimbucher J, Thiede A. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 2008;247:759-65. (Pubitemid 351591510)
38. Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 2007;11:142-7.
39. Zhang X, Tanigawa N, Nomura E, Lee SW. Curability of laparoscopic gastrectomy for gastric cancer: an analysis of 10 years' experience. Gastric Cancer 2008;11:175-80.
40. Fitzgerald RC, Caldas C. E-cadherin mutations and hereditary gastric cancer: prevention by resection? Dig Dis 2002;20:23-31.
41. Miholic J, Meyer HJ, Muller MJ, Weimann A, Pichlmayr R. Nutritional consequences of total gastrectomy: the relationship between mode of reconstruction, postprandial symptoms, and body composition. Surgery 1990;108:488-94.
42. van Kouwen MC DJ, Oyen WJ, de Bruin JH, Ligtenberg MJ, Bonenkamp JJ, van Krieken JH, Nagengast FM. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 2004;10:6456-9.
43. Oelschlager BK, Yigit T, Kaufman JA, Pellegrini CA. Hereditary diffuse gastric cancer. MedGenMed 2005;7:16.
44. Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 2006;202:612-17.
45. Chung DC, Yoon SS, Lauwers GY, Patel D. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283-91.
46. Lynch HT, Kaurah P, Wirtzfeld D, Rubinstein WS, Weissman S, Lynch JF, Grady W, Wiyrick S, Senz J, Huntsman DG. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008;112:2655-63.
47. Caron O, Schielke A, Svrcek M, Fléjou JF, Garzon J, Olschwang S, Sézeur A. Usefulness of prophylactic gastrectomy in a novel large hereditary diffuse gastric cancer (HDGC) family. Am J Gastroenterol 2008;103:2160-1.
48. Gaya DR, Stuart RC, McKee RF, Going JJ, Davidson R, Stanley AJ. E-cadherin mutation-associated diffuse gastric adenocarcinoma: penetrance and non-penetrance. Eur J Gastroenterol Hepatol 2005;17:1425-8. (Pubitemid 41830469)
49. Gaya DR, Stuart RC, Going JJ, Stanley AJ. Hereditary diffuse gastric cancer associated with E-cadherin mutation: penetrance after all. Eur J Gastroenterol Hepatol 2008;20:1249-51.
50. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008;61:25-30.
51. Rubio CA. Five types of pyloric cells in the antral mucosa of the stomach. Pathol Res Pract 1992;188:157-61.
52. Zamboni G, Franzin G, Scarpa A, Bonetti F, Pea M, Mariuzzi GM, Menestrina F. Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Am J Surg Pathol 1996;20:588-98.
53. Thompson IW, Day DW, Wright NA. Subnuclear vacuolated mucous cells: a novel abnormality of simple mucin-secreting cells of non-specialized gastric mucosa and Brunner's glands. Histopathology 1987;11:1067-81.
54. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
55. Carneiro F, Seixas M, Sobrinho-Simoes M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract 1995;191:571-84.
56. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
57. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19. (Pubitemid 121001351)
58. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41:508-17.
59. Corso G, Roviello F, Paredes J, Pedrazzani C, Novais M, Correia J, Marrelli D, Cirnes L, Seruca R, Oliveira C, Suriano G. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol 2007;33:1061-7.
60. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009;69:2050-6.
61. Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007;67:2480-9.